Takeda Pharmaceutical
287 hedge funds and large institutions have $753M invested in Takeda Pharmaceutical in 2022 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 96 increasing their positions, 70 reducing their positions, and 48 closing their positions.
489% more call options, than puts
Call options by funds: $36.6M | Put options by funds: $6.22M
37% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 70
1.25% less ownership
Funds ownership: 4.81% → 3.56% (-1.3%)
4% less funds holding
Funds holding: 298 → 287 (-11)
15% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 48
28% less capital invested
Capital invested by funds: $1.04B → $753M (-$290M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| 1 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$12.6M |
| 2 |
BlackRock
New York
|
+$12.4M |
| 3 |
Millennium Management
New York
|
+$9.27M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.72M |
| 5 |
Goldman Sachs
New York
|
+$7.49M |
Top Sellers
| 1 |
Citigroup
New York
|
-$113M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$107M |
| 3 |
CFM
Capricorn Fund Managers
London,
United Kingdom
|
-$21.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$14M |
| 5 |
HT
HAP Trading
New York
|
-$11.6M |
TAK Hedge Fund Activity: Q1 2022 in Review
287 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2022, worth a combined $753M — down 28% from $1.04B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of TAK and 41 opened new positions — a net loss of 7 holders — while 70 trimmed existing stakes and 96 added.
The largest buyer was Parametric Portfolio Associates, adding an estimated $12.6M. The largest seller was Citigroup, cutting an estimated $113M.
- 287 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2022, down from 298 in Q4 2021.
- Funds reported $753M of Takeda Pharmaceutical stock for Q1 2022, down 28% quarter-over-quarter.
- 41 funds opened new Takeda Pharmaceutical positions in Q1 2022 and 48 closed out, a net change of -7 holders.
- The largest Takeda Pharmaceutical buyer in Q1 2022 was Parametric Portfolio Associates, an estimated $12.6M added.
- The largest Takeda Pharmaceutical seller in Q1 2022 was Citigroup, an estimated $113M sold.
Based on aggregated 13F filings for Q1 2022.